Form 4 for SCTX Scribe Therapeutics, Inc.

Accepted 2026-07-27 21:42:12 ET · period of report 2026-03-13 · accession 0001781292-26-000007 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
DI	2026-07-27 21:42	2026-07-23	SCTX	Lucas Svetlana	Chief Business Off	P - Purchase	$15.00	+3,000	3,000	New	+$45.0K
DM	2026-07-27 21:42	2026-03-13+	SCTX	Lucas Svetlana	Chief Business Off	A - Grant	$0.00	+228.4K	109.4K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2026-07-23	P	A	3,000	$15.00	3,000	I By Spouse	—	—
2	Derivative	Stock Option (Right to Buy)	2026-03-13	A	A	9,547	$0.00	9,547	D	$19.13 · — to 2036-03-12	9,547 Common Stock	(F1) The transaction occurred prior to the Issuer's registration of a class of equity securities under Section 12 of the Exchange Act in connection with the Issuer's initial public offering, and the transaction is reported herein pursuant to Rule 16a-2(a). (F2) The option is fully vested.
3	Derivative	Stock Option (Right to Buy)	2026-07-23	A	A	109,426	$0.00	109,426	D	$15.00 · — to 2036-07-22	109,426 Common Stock	(F3) The options will vest as to 1/48 of the total shares monthly over four years, with the first tranche scheduled to vest on August 23, 2026, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
4	Derivative	Performance-based Stock Option (Right to Buy)	2026-07-23	A	A	109,426	$0.00	109,426	D	$15.00 · — to 2036-07-22	109,426 Common Stock	(F4) The options are eligible to vest upon the achievement of certain market-based performance criteria during a performance period beginning on July 23, 2026 and ending on July 23, 2029, subject to the Reporting Person's provision of service to the Issuer on each vesting date.